Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience

Basit Öğe Kaydı
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorDemirtürk, Neşe
dc.contributor.authorYıldız, Orhan
dc.contributor.authorÇelen, Mustafa Kemal
dc.contributor.authorÇelik, İlhami
dc.contributor.authorBarut, Şener
dc.contributor.authorUral, Önur
dc.contributor.authorBatırel, Ayşe
dc.contributor.authorMıstık, Reşit
dc.contributor.authorŞi̇mşek, Funda
dc.contributor.authorAsan, Ali
dc.contributor.authorErsöz, Gülden Munis
dc.contributor.authorTürker, Nesrin Akbaş
dc.contributor.authorBilgin, Hüseyin
dc.contributor.authorKınıklı, Sami
dc.contributor.authorKarakeçili, Faruk
dc.contributor.authorZararsız, Gökmen
dc.contributor.authorGünal, Özgür
dc.contributor.authorAkhan, Sıla Cetin
dc.contributor.authorTulek, N.
dc.contributor.authorİnan, Dilara
dc.contributor.authorÇaǧatay, Arif Atahan
dc.contributor.authorGürbüz, Yunus
dc.contributor.authorŞener, Alper
dc.contributor.authorÇelikbaş, Aysel Kocagül
dc.contributor.authorÇetinkaya, Rıza Aytaç
dc.contributor.authorKadanalı, Ayten
dc.contributor.authorHakyemez, İsmail Necati
dc.contributor.authorKuruüzüm, Ziya
dc.contributor.authorÖzel, Selcan Arslan
dc.contributor.authorKorkmaz, Pınar Yagiz
dc.contributor.authorTuna, Nazan
dc.contributor.authorSaltoǧlu, Neşe
dc.contributor.authorTarakçı, Hüseyin
dc.contributor.authorUysal, Burcu
dc.contributor.authorKaragöz, Ergenekon
dc.contributor.authorKoçulu, Safiye
dc.contributor.authorAyaz, Celal
dc.contributor.authorGüzel, Deniz Kamalak
dc.contributor.authorTürkoğlu, Emine
dc.contributor.authorDemir, Nazlım Aktuğ
dc.contributor.authorŞimşek, Sümeyra
dc.contributor.authorKantürk, Arzu
dc.contributor.authorAkça, Mustafa Özgür
dc.contributor.authorEvik, Güliz
dc.contributor.authorÖrmen, Bahar Kopraman
dc.contributor.authorSili, Uluhan
dc.contributor.authorHatipoǧlu, Çiǧdem Ataman
dc.contributor.authorBinay, Umut Devrim
dc.contributor.authorKılıç, Sırrı
dc.contributor.authorArslan, Kader
dc.contributor.authorYenilmez, Ercan
dc.contributor.authorÇomoǧlu, Şenol
dc.contributor.authorKoç, Meliha Meriç
dc.contributor.authorGökgöz, Altan
dc.contributor.authorDursun, Zehra Beştepe
dc.contributor.authorSümer, Şua
dc.contributor.authorHeper, Yasemin
dc.contributor.authorYíldírmak, Taner T.
dc.contributor.authorÖztürk, Sinan
dc.contributor.authorGüğül, Tuğba Demirel
dc.contributor.authorYüce, Zeynep Türe
dc.date.accessioned2021-07-08T08:15:11Z
dc.date.available2021-07-08T08:15:11Z
dc.date.issued2020en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalıen_US
dc.descriptionWOS:000535263200004
dc.descriptionPMID: 32412901
dc.description.abstractBackground/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r ± DSV ± RBV combination regimen in a real-world clinical practice. Materials and Methods: Data from HCV genotype 1 and 4 patients treated with OMV/PTV/r ± DSV ± RBV (n=862) in 34 centers across Turkey between April 1, 2017 and August 31, 2018 were recorded in a large national database. Demographic, clinical, and virologic data were analyzed. Results: The mean age of the patients was 55.63, and 430 patients (49.9%) were male. The majority had HCV genotype 1b infection (77.3%), and 66.2% were treatment-naïve. Non-cirrhosis was present at baseline in 789 patients (91.5%). SVR12 rate was 99.1% in all patients. Seven patients had virologic failure. No significant differences were observed in SVR12 according to HCV genotypes. HCV RNA was undetectable at treatment week 4 in 90.9%, at treatment week 8 in 98.5%, and at the end of treatment (EOT) in 98.9%. SVR12 ratio was significantly higher in the non-cirrhotic patients compared to that in the compensated cirrhotic patients. Rates of adverse events (AEs) in the patients was 59.7%. Conclusion: The present real-life data of Turkey for the OBV/PTV/r ± DSV ± RBV treatment of patients with HCV genotype 1b, 1a, or 4 infection from 862 patients demonstrated high efficacy and a safety profile. © Copyright 2020 by The Turkish Society of Gastroenterologyen_US
dc.identifier.citationAygen, B., Demirtürk, N., Yıldız, O., Çelen, M. K., Çelik, İ., Barut, Ş. ve diğerleri. (2020). Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turkish Journal of Gastroenterology, 31(4), 305-317.en_US
dc.identifier.doi10.5152/TJG.2020.19197
dc.identifier.endpage317en_US
dc.identifier.issn1300-4948
dc.identifier.issn2148-5607
dc.identifier.issue4en_US
dc.identifier.pmid32412901
dc.identifier.scopus2-s2.0-85084787334
dc.identifier.scopusqualityQ3
dc.identifier.startpage305en_US
dc.identifier.trdizinid419482
dc.identifier.urihttps://www.turkjgastroenterol.org/en/real-world-efficacy-safety-and-clinical-outcomes-of-ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin-combination-therapy-in-patients-with-hepatitis-c-virus-genotype-1-or-4-infection-the-turkey-experience-experience-136659
dc.identifier.urihttps://hdl.handle.net/11468/7219
dc.identifier.volume31en_US
dc.identifier.wosWOS:000535263200004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorÇelen, Mustafa Kemal
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofTurkish Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic hepatitis Cen_US
dc.subjectDasabuviren_US
dc.subjectHCV genotypes 1 and 4en_US
dc.subjectOmbitasviren_US
dc.subjectParitapreviren_US
dc.subjectReal-world effectivenessen_US
dc.titleReal-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experienceen_US
dc.titleReal-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Real-world efficacy and safety of Ledipasvir + Sofosbuvir and.pdf
Boyut:
1.15 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu